A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study of TS-142 in Patients With Insomnia Disorder
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Vornorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
Most Recent Events
- 18 Dec 2023 Status changed from recruiting to completed.
- 07 Sep 2022 Status changed from not yet recruiting to recruiting.
- 16 Aug 2022 Planned initiation date changed from 1 Jul 2022 to 1 Aug 2022.